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Highlights 
 
 We summarize a collection of findings and approaches by researchers working in the field, 
highlighting key considerations for new and current researchers and intended as a prologue 
to this special issue of the Nitric Oxide Journal.  
 We attempt to strike an informative and cautionary note, by highlighting key considerations 
as opposed to specific study recommendations. 
 We include suggestions on what to focus on and/or do better.  
 New data is provided to illustrate by example. 
 
  
Abstract 
It is now recognised that administration of oral nitrate (NO3
-
), in its various forms, increases the level 
of nitric oxide (NO) metabolites in the circulation of humans.  Its application to modulate physiology 
and alleviate cardiovascular dysfunction in some patients is now recorded and shows particular 
promise in hypertension, in modifying platelet activation/aggregation, and in conditions where tissue 
ischemia prevails. The potential of oral NO3
-
 to modify exercise/performance via elevation of plasma 
nitrite concentration ([NO2
-
]) has been applied across a range of human test systems. Herein we 
discuss how the choice of NO3
- 
source, route of administration and resulting pharmacokinetics might 
influence the outcome of physiological measures and potentially contribute to discrepancies in 
performance trials. There are but a few examples of detailed pharmacokinetic data on which the 
majority of researchers base their test protocols in different cohorts/settings. We compare and contrast 
the results of key publications with the aim of highlighting a consensus of our current understanding 
and critical considerations for those entering the field. 
 
Keywords: Nitrite; Nitrate; Pharmacokinetics; Exercise. 
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Introduction 
Administration of oral nitrate (NO3
-
), in its various forms, increases the level of nitric oxide (NO) 
metabolites in blood.  Its application to modulate physiology and alleviate cardiovascular dysfunction 
shows particular promise in certain clinical conditions and patient cohorts, including reduction of 
mean arterial pressure in hypertension [1, 2], effective quiescencing of platelet activation/aggregation 
[3], and reduce risk in conditions where tissue ischemia prevails  [4]. However, it is the potential of 
oral NO3
-
 to modify exercise/performance via elevation of plasma nitrite concentration ([NO2
-
]) that 
has been applied across a range of human test systems, from the effects of walking distance in a 
sedentary population [5] to enhancing performance in elite athletes [6]. 
 
There is a general consensus on the principal pathways and primary mechanisms involved in the 
conversion of oral NO3
-
 to circulating NO2
-
 and NO.  However, there remains significant variation in 
the levels of NO metabolites attained in the plasma and it is presently not known which levels are 
sufficient to enhance physical performance in a particular setting. Most investigators (but not all) are 
aware of the many controllable factors that introduce variance and take measures to counter these (e.g. 
cohort choice and dietary restriction). We must also acknowledge other, potentially less obvious 
sources of variation in our research designs or otherwise risk misinterpreting our performance 
findings.  
 
Herein we discuss how the choice of NO3
- 
source, route of administration and resulting 
pharmacokinetics might influence the outcome of physiological studies and potentially contribute to 
discrepancy in performance trials. There are but a few examples of detailed pharmacokinetic data on 
which the majority of researchers base their test protocol in different cohorts/settings. We compare 
and contrast the results of key publications with the aim of highlighting to this readership a consensus 
of our current understanding and critical considerations for those entering the field. Perhaps 
opportunity exists in exploiting these observations.  
 
Nitrate (NO3
-
)
 
source 
The source of NO3
-
 influences the concentration, bioavailability, subject compliance and route of 
administration. Foodstuffs contain varying concentrations of NO3
-
, with leafy vegetables and beetroot 
(BR) a relatively rich source [7]. The awareness and consumption of NO3
-
 has been enhanced by the 
recent commercialisation of BR, chard and rhubarb concentrates in products such as Beet it® (James 
White Drinks) and Go+Nitrate® gel (Science in Sport). With a burgeoning awareness of the potential 
importance of NO3
-
 in sport and exercise, an ever-increasing variety of NO3
-
 fortified products are 
becoming commercialised, ranging from sport bars and lozenges to BR capsules. Importantly, NO3
-
 
salts (in solution or via capsule) are readily available for both oral and intravenous administration and 
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as such provide a convenient and essential pharmacologic NO3
-
 standard with which to compare 
results from human studies in various cohorts/settings. However, as outlined below, this may not 
translate to studies involving BR, or chard concentrate. In order for investigators to compare the effect 
of NO3
-
 supplementation on exercise and performance, it is first necessary to consider, are we 
comparing like-for-like? New products include a NO3
-
 rich flapjack bar and NO3
-
 / NO2
-
 crystals 
which dissolve to produce a beverage. While all of these products likely have physiological effects, 
they have not been directly compared and it is possible that a given NO3
-
 content in these products 
may differentially influence the peak (and time to peak) plasma [NO3
-
] and [NO2
-
], with implications 
for performance outcomes. 
 
A further consideration is what other bio-active components exist within each product – a question 
rarely addressed. An interesting healthcare product is being marketed by Neogenis (Neo40) which 
contains NO3
-
 and NO2
-
 but also concentrate from berry and other components aimed at enhancing 
delivery. Certainly early clinical studies show peak plasma [NO2
-
] is attained within ~20 min which is 
considerably shorter than that required for BR preparations (typically ~2hrs) [8]. A further product 
being developed is in the form of a lozenge which also shows early plasma increases in [NO3
-
] and 
[NO2
-
]. This may suggest that inclusion of a modest amount of NO2
-
 in the preparation may be an 
advantage to facilitate the early onset of physiological effects, and holding the NO3
-
 source in the 
buccal cavity may also speed up NO3
-
-NO2
-
NO metabolism. In vitro modelling of NO3
-
 reduction in 
simulated gastric and buccal medium however shows that most bacterial reductases exhibit limited 
function at lower pH. It is therefore interesting to note that commercial products of BR, or chard, 
exhibit acidic pH (typically 3-5) which can enhance shelf life. This in itself is unlikely to affect the 
first pass absorption of nitrite and nitrate from the stomach and proximal small intestine into blood, 
but with second or subsequent administration could hinder second pass buccal NO3
-
 reduction (via the 
enterosalivary circulation). It is also critical to consider the availability of “free” inorganic NO3
- 
contained within the organic source (such as BR, or chard). Whilst NO3
-
 analysis using VCl3/HCl at 
85˚C or other chemical cleavage reagents are able to cleave the total NO3
-
 content for detection by 
ozone based chemiluminescence, application of in vitro NO3
-
 reductases under conditions expected in 
the buccal cavity or stomach yields very little NO2
-
 from BR, or chard, despite 100% yield from 
KNO3 under the same laboratory conditions (P.E.J. unpublished observations). This further confirms 
the need for first pass digestion prior to sequestration of NO3
-
 already in plasma.    
 
Nitrate (NO3
-
)
 
pharmacokinetic parameters 
The variety of NO3
-
 sources present different challenges, ranging from subject compliance / 
palatability, pharmacovigilance and differing pharmacokinetic profiles. Moreover, these challenges 
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are coupled with a complex NO3
-
 biochemistry, where inter-biological variation, oral and gut bacteria 
capacity and saliva flow rate are but a few variables determining the fate of NO3
- 
metabolism. 
 
Velzen et al, [9] demonstrated the source of NO3
-
 dictates the pharmacokinetic profile of plasma NO3
-
. 
They found bolus administration of either NaNO3 (365 mg NO3
-
), spinach (564 mg NO3
-
), lettuce 
(1014 mg NO3
-
) or BR (643 mg NO3
-
), resulted in different peak NO3
-
 attained and time to reach 
maximal level, consistent with the extent of NO3
-
 loading from different dietary sources. Interestingly, 
the half-life was consistent at 6 hrs irrespective of source (Table 1). These findings remain as 
reference values, but in-depth insight is gained from more recent studies. Wylie et al, [10] recently 
considered the impact of dose and volume load, whereby the bolus administration of Beet it (70 ml, 
140 ml and 280 ml) provided 4.2 mmol, 8.4 mmol and 16.8 mmol NO3
-
, a range encompassing most 
performance/exercise studies to date. The peak in plasma [NO3
-
] and [NO2
-
] was noticeably delayed 
with increasing dose/volume, with a corresponding increase in time in the circulation (t½).  This is in 
good agreement with the work of Kapil et al [11]. The increase in plasma [NO2
-
] relative to the 
increase in plasma [NO3
- 
] (Δ[NO2
-]/ Δ[NO3
-
] ratio, as defined in Table 1) was relatively consistent 
(1.0-1.2) and is in keeping with the work of most using BR [11-14], but inconsistent with Webb et al 
[3] (~0.5). Of those groups administering KNO3
- 
(capsule or in solution) the results are also very 
consistent (0.8-1.0) other than the work of Velmuragan et al, [12] which is modestly higher (1.4-2.3) 
in comparison. There is some consistency in terms of time to peak plasma [NO3
-
], being between 1 - 3 
hrs, and a plasma t½ of >6 hrs is found irrespective of KNO3 dose (4 - 24 mmol).   
 
In addition, taken together there is good evidence that time to peak NO3
-
 may depend on the source of 
NO3
-
, although there are notable exceptions [11]. In general, a KNO3 solution/capsule and NO3
-
 
containing gel (SiS Go+Nitrate) appear to exhibit an earlier peak (~1hr) when compared with BR at a 
similar loading dose. Conversely, there is some evidence to indicate that the overall yield from BR 
may be higher in comparison to other NO3
-
 sources such as swiss chard (SiS Go+Nitrate, based on 
area under curve analysis over 24 hrs, Figure 1). However, care must be taken in over-interpreting this 
early observation. It is entirely possible that different forms of nitrate delivery (whether gel, food, or 
liquid) may in itself dictate plasma pharmacokinetics. This can only be resolved by appropriate cross-
over studies in the same individuals. 
 
Importantly, there is discrepancy in the level of plasma [NO2
-
] attained per unit amount of NO3
-
 
administered between groups (0.5 – 2.5) and even within individual subjects over a prolonged period 
of time. Of those utilising a similar BR source, in one or two repeated tests there is an apparent split 
between those exhibiting high relative yield [12-14] and those finding significantly lower yield [3, 
11]. In these examples, volume of NO3
-
 administration does not appear to be the cause of the 
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discrepancy, neither does this appear to be methodological (since all studies essentially use ozone-
based chemiluminescence to measure plasma NO metabolites).  
 
Remaining questions are whether studies aimed at testing exercise performance should either ensure 
tests are carried out at the peak plasma [NO2
-
] and/or whether it might be more appropriate to aim for 
a minimal effective increase (for example 200 nM above baseline or X-fold change). These factors are 
important to consider when comparing results between groups and in chronic administration studies 
where it may be extremely difficult to monitor plasma  [NO2
-
] as blood samples would have to be 
collected prior to, and following, each dosing to identify the change. Moreover, as a rule of thumb, 
classic pharmacological studies suggest >50% of experimental measures should be undertaken around 
the point of interest in order to yield accurate data on peak plasma [NO2
-
] which may be impractical 
unless pre-determined in that particular subject.  
 
Individual versus Group Variation 
This is difficult to interpret from grouped data expressed as mean±error. Certainly in our hands [13] 
there remains noticeable variation in both time to peak, and peak plasma [NO2
-
] per [NO3
-
] between 
individuals in an otherwise closely matched cohort; this despite implementing a 12 hr fast (thus 
reducing baseline variance) and maintenance of an essentially NO3
-
 free diet over 24 hrs (Figure 2). It 
is important to note that the study conditions represent a ‘best case’ scenario that adhered to the key 
considerations suggested by this manuscript. Interestingly, there is overall a consistent area under the 
curve for plasma [NO2
-
] and plasma [NO3
-
], comparing individuals across 24 hrs, which implies the 
total yield may be similar.  One individual (out of seven) did appear to exhibit an enhanced AUC for 
ΔNO2
- 
compared to the other individuals. It is reasonable to speculate that this individual variation 
could be due to genetic variation, chronobiology and/or variation in oral/buccal hygiene (see below 
for a fuller discussion of these factors). Further to this, baseline plasma [NO3
-
] is remarkably 
consistent across most research groups, whereas baseline plasma [NO2
-
] varies considerably (~80-400 
nM). It is tempting to speculate this reflects mainly differences in dealing with and/or storing the 
plasma sample as we and others have demonstrated [15]. There is no observable trend to indicate 
higher baseline plasma levels influence the peak yield, but this remains to be tested directly. Figure 3 
shows the scatter between measured plasma [NO3
-
] and [NO2
-
] in seven subjects with peripheral 
arterial disease tested on at least 5 different occasions (many as random surprise tests) as they 
received 3 separate doses/week for 3 months of 70 ml (4.2 mM) BR in the form of Beet it. Blood 
samples were consistently taken 3 hrs post-ingestion. It is apparent that the within-subject responses 
can be quite variable with no apparent trend with time or repeat dosing. Currently, the effects of 
source/mode of NO3
-
, dosage and frequency of NO3
-
 administration on the conversion rate or the 
maintenance of a minimum “active” plasma [NO2
-
] over prolonged periods is untested. 
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The influence of diet is complicated. There is evidence that there is considerable cross-talk between 
dietary nitrate-nitrite-NO and the endogenous NOS pathways [16]. Certainly diet influences baseline 
plasma [NO2
-
] and [NO3
-
] levels. However Miller et al, [14] showed convincingly this has only a 
minimal (but measurable) overall effect on the peak and t½ of plasma [NO2
-
]/[NO3
-
] when measured 
following an acute NO3
-
 load across 24 hrs. Yet another factor which should be considered is 
chronobiological variation. It has been shown that chronobiological variations in systemic NO 
production and urinary nitrate excretion do occur [17]. It is unknown whether a contributor to such 
variation might be a chronobiological fluctuation in human nitrate uptake and/or chronobiological 
variation in nitrite reduction. Nevertheless, future trials involving multiple human participants can (to 
some extent) control for this potential confounder by ensuring that the study design allows for 
individuals to ingest nitrate, and to have biofluids/tissues sampled, at the same times of day. Of 
relevance, Velmuragan et al, [12] observed a significant difference with gender, where females 
typically exhibit significantly higher yields for the same given dose of KNO3/BR, compared to their 
male counterparts. This also aligned with different physiological effect (e.g. blood pressure 
reduction). This has not been tested in terms of exercise performance with the majority of studies 
having been conducted in male subjects.  
 
Several other factors have been implicated and are particularly relevant to a trained cohort who are 
invariably on a controlled diet and have a healthy lifestyle. These include (but are not limited to) 
demographics of the cohort being studied, genetic variation, chronobiology and variation in 
oral/buccal hygiene. The latter has not been studied directly in terms of variation in a normal buccal 
regimen, but the early work of Kapil et al, [18] demonstrated how mouthwash effectively decreased 
NO3
-
 reducing capacity. More recently, we have shown that this is completely dependent on the 
mouthwash being used – whether antibacterial or antiseptic (typically antibacterial mouthwashes kill 
or hinder bacterial reproduction whereas antiseptic mouthwashes kills or hinders the reproduction of 
multiple microorganisms, including bacteria, fungi and viruses. J.D.A. unpublished observations). The 
levels of [NO2
-
] and [NO3
-
] in saliva and in plasma are completely dependent on the efficacy of the 
mouthwash. With such biological variation, coupled with the study variables determining the fate of 
NO3
- 
metabolism, to enable inter-study comparison future studies must consider: 
1) normalising NO3- load to body mass (as opposed to administering a set NO3- load), or 
2) ensuring a minimum effective increase in plasma [NO2-]/ [NO3-] in a particular cohort, or 
3) adjusting the NO3- load in each subject to attain a pre-set physiologically effective plasma 
level.  
 
Nitrate pharmacokinetic parameters: Impact on exercise performance 
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In recent years, there has been a plethora of studies published on the effect of NO3
-
 supplementation 
on exercise performance. These have manipulated a variety of factors to elucidate the ergogenic 
potential of dietary NO3
-
 supplementation including: the ‘dose’ of NO3
-
 administered; the duration of 
NO3
-
 supplementation (acute versus more chronic); the duration and intensity of the exercise 
performance trial; the nature of the exercise (continuous or intermittent); the environmental conditions 
(hypoxia vs. normoxia); and the characteristics of the participants, particularly in relation to training 
status.   
 
The bolus or daily amount of NO3
-
 administered in exercise performance studies has ranged from 
about 4 mmol to about 12 mmol, with ‘positive’ effects most often reported with higher NO3
-
 doses. 
Wylie et al, [10] investigated the influence of various doses (4.2, 8.4 and 16.8 mmol) of ingested NO3
-
 
in BR juice on plasma [NO3
-
] and [NO2
-], and also the ‘dose-response’ relationship between acute 
NO3
-
 ingestion and exercise performance. Higher doses of NO3
-
 resulted in higher peak values of 
plasma [NO3
-
] and [NO2
-
], with the peak in plasma [NO3
-
] occurring earlier (1-2 hours post-ingestion) 
than the peak in plasma [NO2
-
] (2-3 hours post-ingestion). With the assumption that greater plasma 
[NO2
-
] indicates greater NO bioavailability, these results have been utilised to investigate the 
influence of NO3
-
 dose on exercise performance. An amount of 4.2 mmol NO3
-
 did not significantly 
improve high-intensity exercise performance. In contrast, 8.4 and 16.8 mmol NO3
-
 doses both resulted 
in improved exercise performance, but 16.8 mmol was no more effective than 8.4 mmol. These results 
indicate that there may be a ‘threshold’ amount of NO3
-
 that should be ingested (with a corresponding 
‘threshold’ elevation of plasma [NO2
-
]) for exercise performance benefits to be obtained, but also that, 
beyond that threshold, extra NO3
- 
ingestion will not further improve performance. This latter result 
may be important in informing the development of both safe and efficacious NO3
-
 supplementation 
regimens. Based on the results of Wylie et al, [10], ‘negative’ results in studies utilising relatively low 
doses of NO3
-
 should not be considered surprising.  
 
The early studies on NO3
-
 ingestion and exercise performance involved subjects consuming NO3
- 
salts 
or BR juice for ~5-7 days [19, 20]. However, later studies [21] indicated that the O2 cost of sub-
maximal exercise could be reduced within just 2-3 hours of NO3
-
 ingestion with this effect being 
maintained if supplementation was continued for 15 days. The finding that exercise efficiency could 
be improved acutely stimulated a number of research groups to investigate whether exercise 
performance could also be improved following a single ‘bolus’ of NO3
-
. Notwithstanding the issue of 
sufficient NO3
-
 dosing alluded to earlier, the results from this approach have been mixed. The 
mechanistic basis for the early physiological effects of NO3
-
 is unclear but could include effects of 
NO2
-
 or NO on mitochondrial function, O2 delivery to and within muscle, and substrate utilisation. It 
has been reported that longer-term NO3
-
 supplementation (5-7 days) can result in changes in 
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mitochondrial [22] and contractile [23] proteins that would be expected to enhance skeletal muscle 
metabolic and mechanical efficiency. It would seem unlikely that these changes could be fully 
effected within a few hours of NO3
-
 ingestion and therefore the duration of NO3
-
 supplementation is 
likely to introduce variability into the potential efficacy of NO3
-
 on the physiological responses to 
exercise. 
 
The influence of NO3
-
 supplementation on a wide range of exercise activities has been investigated, 
ranging from 500 m kayaking [24] to 50 miles cycling [25], with predictably mixed results. While the 
majority of studies to date have assessed the influence of NO3
-
 supplementation on continuous 
exercise, a few have considered possible effects on intermittent high-intensity exercise tests which are 
reflective of the pattern of exertion during team sports. While, once again, the results of these studies 
have been mixed, owing at least in part to differences in dosing and duration of supplementation, 
there is evidence that NO3
-
 can be ergogenic in such activities [10]. With such discrepancies in the 
efficacy of NO3
- 
supplementation on exercise performance, several activity-specific factors need to be 
considered. 
 
Environmental conditions  
Conditions of low O2 availability would be expected to lower NO synthase (NOS) function and 
therefore to potentially augment NO production via the reduction of NO2
-
. Consistent with this, it 
appears that ambient O2 influences the ability of NO3
-
 ingestion to enhance exercise performance. In 
hypoxia, intramuscular perturbation of phosphate-linked substrates and metabolites is blunted when 
exercise is preceded by NO3
-
 ingestion [26] and cycle time trial [13] and incremental exercise [27] 
performance in hypoxia is improved following NO3
-
 supplementation. The recovery of muscle 
phosphocreatine concentration, an index of oxidative capacity, is enhanced in hypoxia but not 
normoxia following NO3
-
 supplementation and this effect appears to be related to improved muscle 
oxygenation [28]. To date, improved exercise performance following NO3
-
 supplementation has been 
more consistently observed in hypoxia compared to normoxia, and environmental conditions are 
therefore another factor worthy of consideration when assessing differences between studies.  
 
Fitness status 
Another important consideration is the fitness/training status of the participants in NO3
-
 
supplementation studies. Subjects who are aerobically trained, and especially elite endurance athletes, 
will have experienced numerous adaptations that may limit the possible benefits of NO3
-
 
supplementation. These adaptations include: greater NOS activity; greater muscle oxygenation owing 
to greater muscle capillary density; mitochondrial proliferation and possibly improved mitochondrial 
efficiency; higher baseline plasma [NO2
-
]; and lower proportion of type II muscle fibres. Conversely, 
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subjects with compromised cardiovascular and skeletal muscle systems often show peripheral tissue 
maladaptations to these chronic disease conditions which may include capillary density rarefaction, a 
reduction in mitochondrial number and efficiency, and a higher proportion of type II muscle fibres. 
Numerous exercise performance studies in disease states such as peripheral arterial disease [29], 
chronic heart failure [30] and pulmonary diseases [31] are starting to emerge. 
 
Although there is evidence that the exercise performance of elite athletes can be improved by NO3
-
 
supplementation [23], it does appear that better trained athletes benefit less compared to lesser trained 
individuals, at least when a similar NO3
-
 dose is ingested. It is important to note, however, that it is 
possible that elite athletes will respond better to NO3
-
 supplementation with larger doses or more 
protracted supplementation regimens. Irrespective of training status, it has been suggested that there 
may be ‘responders’ and ‘non-responders’ to NO3
-
 supplementation [24], and this also may explain 
variability between studies as alluded to earlier. It remains unclear, at what stage in the NO3
-
-NO2
-
-
NO pathway, ‘non-responders’ are being ‘limited’ in their response. Identifying reasons for the inter-
individual variability in the response to NO3
-
 supplementation must be an important future research 
goal. 
 
Final perspectives 
We have selectively drawn on the work of several groups to highlight important similarity but also 
noticeable discordance in results. These key studies were typically undertaken using a back-to-basics 
pharmacological approach, and it seems worthwhile for investigators comparing new cohorts, exercise 
programs or patients to at least first ensure that the axis of NO3
-
-NO2
-
-NO metabolism is as expected 
in their particular cohort or model. It will also be critical to first establish whether individual variation 
could be greater than the effect being tested. It is unlikely that we will be able to advance our 
understanding and significantly exploit potentially ergogenic and therapeutic properties of oral NO3
-
 
supplementation until these processes are elucidated. 
 
Some useful future studies could include a comprehensive assessment of nitrate pharmacokinetics, 
comparing different sources and routes of administration of NO3
- 
in the same individual(s) in a 
carefully controlled crossover study. The focus of this manuscript was to highlight subtle differences 
in the pharmacokinetic profile of plasma NO metabolites following either KNO3 solution/salt, NO3
-
 
gel (chard or rhubarb), or BR. These various NO3
-
 sources may each offer an advantage in a particular 
setting. Once the kinetic profile is deciphered for the particular ergogenic aid in the study cohort, 
timing of a bolus / serial dose can be recommended and should be based on achieving either a 
minimum effective increase or a pre-defined plasma [NO3
-
] or [NO2
-
]. We suggest that it should then 
be considered whether an individual would benefit from initiating exercise at peak plasma [NO3
-
] or 
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[NO2
-
] and that it should be kept mind that this is synergistically related to the environmental 
conditions and the individual’s variation in pharmacokinetic parameters. Essential considerations are 
summarised in Figure 4. 
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Figure Legends 
 
Figure 1 – Representative data showing (A) plasma Δ[NO2
-
] and (B) plasma Δ[NO3
-
] in humans for 
24 hrs following a single bolus dose of BR or SiS Go+Nitrate. Δ refers to plasma [NO2
-
] or [NO3
-
] 
minus basal plasma [NO2
-
] or [NO3
-
], respectively. Data adapted from [10, 13].  
 
Figure 2 – Plasma [NO2
-
] (A) and plasma [NO3
-
] (B) measured in 6 healthy individuals (age 34 ± 6 
years) following administration of 2 x 2.9 mmol [NO3
-
] in the form of SiS Go+Nitrate, showing 
individual results across 24 hrs. Δ refers to plasma [NO2
-
] or [NO3
-
] minus basal plasma [NO2
-
] or 
[NO3
-
], respectively. Adapted from [12]. 
 
Figure 3 – Measurement of plasma [NO2
-
] and [NO3
-
] in 7 individuals on 5 separate occasions. 
Subjects received 3 weekly doses of Beet it (4.2 mmol) over a 3 month period. Blood measures were 
undertaken 3 hrs post administration. All administrations were early in the day (am) - 3 hours prior to 
blood sampling. All subjects were fasted and remained so during the course of the study. NOx; Nitric 
oxide metabolites.  
 
Figure 4 – Summary of factors to consider prior to embarking on a NO3
-
 supplementation research 
study.  
 
Reference NO3
-
 
source  
Dose/ 
volume 
Plasma NO3
-
 
Δ (baseline – 
max) 
Plasma NO2
-
 Δ 
(baseline – 
max) 
ΔNO2
-
/ΔNO3
-
 
(x 10
-3
) 
T-max 
plasma 
[NO3
-
] 
T-max 
plasma 
[NO3
-
] 
T ½ 
[NO3
-
] 
T ½ 
[NO2
-
] 
Lundberg et 
al, [32] 
Oral 
(liquid) 
NaNO3  
~8.5 mmol  
302 µM  
(30 – 432) 
269 nM  
(123 – 392) 
0.891 0.5 hr 1.5 hrs - - 
Velzen et al, 
[9] 
KNO3 IV 
oral food 
oral food 
oral food 
4.2 mmol 
6.5 mmol 
11.7 mmol 
7.4 mmol 
- 
- 
- 
- 
- 
- 
- 
- 
 0.6  hr 
1.8 hr 
1.54 hr 
1.75 hr 
- 
- 
- 
- 
5 
5 
6.7 
6.1 
- 
- 
- 
- 
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Kapil et al, 
[11] 
Oral 
(Capsule) 
KNO3:  
24 mmol  
12mmol 
4mmol 
 
1300 µM  
670 µM 
170 µM 
 
1100 nM  
600 nM 
150 nM 
 
0.846 
0.896 
0.882 
 
3 hr 
2 hr 
1.5 hr 
 
2.5 hr 
1 hr 
1 hr 
 
~ 6 hr 
 
>24 hr 
Velmuragan 
et al, [12] 
Oral KNO3  8mmol: 
Male 
 
female 
 
180 µM  
(20-200) 
215 µM  
(35-250) 
 
250 nM  
(100-350) 
500 nM  
(50-550) 
 
1.389 
 
2.326 
 
3 hr 
 
3 hr 
 
3 hr 
 
3 hr 
 
- 
 
- 
 
- 
 
- 
Kapil et al, 
[11] 
Oral 
(liquid) 
BR  250ml  ~ 
5.5mmol 
175 µM  
(25 to 200) 
200 nM  
(400 - 600) 
1.142 1 hr 2.5 hr - - 
Kenjale et 
al, [29] 
Oral 
(liquid) 
BR 500ml ~ 
5.2mmol 
- 791 nM 
(151 – 942) 
- 2 hr 2 hr - - 
Lansley et 
al, [5] 
Oral 
(liquid) 
BR – 500 ml 
~ 6.2 mmol 
- 334 nM 
(241 – 575) 
- 2 hr 2 hr - - 
Larsen et al, 
[19] 
Oral 
(liquid) 
NaNO3 0.1 
mmol 
55 µM 
(27 – 182) 
102 nM (124 - 
226) 
1.854 45 min 45 min - - 
Webb et al, 
[3] 
Oral 
(liquid) 
BR ~11.2 
mmol, 500ml 
350 µM 
(25 - 375) 
180nM 
(420 – 600) 
0.514 1.5 hr 3 hr ~ 6.5 hr ~5.5 hr 
Muggeridge 
et al, [33] 
Oral 
(liquid) 
BR, ~ 5 mmol, 
70 ml 
107 µM 
(42.8 - 150) 
270 nM 
(408 - 678) 
2.519 3 hr 3 hr - - 
Wylie et al, 
[10] 
Oral 
(liquid) 
 
16.8 mmol (in 
280 ml) 
 
8.4 mmol (in 
140 ml) 
 
4.2 mmol (in 
70 ml) 
570 µM 
(30-600) 
 
270 µM 
(30-300) 
 
160 µM 
(30-190) 
645 nM 
(80-725) 
 
395 nM 
(80-475) 
 
120 nM 
(80-200) 
1.132 
 
 
1.463 
 
 
0.75 
 
2 hr 
 
 
1 hr 
 
 
1 hr 
4 hr 
 
 
2 hr 
 
 
2 hr 
9.5 hr 
 
 
7 hr 
 
 
6 hr 
8 hr 
 
 
6 hr 
 
 
7.5 hr 
Velmuragan 
et al, [12] 
Oral 
(liquid) 
BR 3.1 mmol: 
male 
 
 
female 
 
100 µM 
(20-120) 
 
125 µM 
(25-150) 
 
150 nM 
(200-350) 
 
250 nM 
(300-550) 
 
1.5 
 
 
2.0 
 
3 hr 
 
 
- 
 
3 hr 
 
 
- 
 
- 
 
 
- 
 
- 
 
 
- 
Miller et al, 
[14] 
Oral 
(liquid) 
BR - 8.5 mmol  350 µM 800 nM 2.286 2 hr 2-3 hr 8 hr >7 hr 
Muggeridge 
et al, [33] 
SiS gel Chard gel - 5.8 
mmol 
350 µM 
(67-416) 
179 nM 
(155-334) 
0.503 1 hr 1-
1.5hr 
6 hr 5 hr 
Table 1 –Pharmacokinetic summary of acute nitrate loading. Summary of NO3
-
 pharmacokinetic 
parameters from key papers. [Blue shade]: inorganic potassium nitrate (KNO3), sodium nitrate 
(NaNO3) or food source. [Green shade]: BR, beetroot juice. [White shade]: Swiss chard gel. Δ refers 
to plasma [NO2
-
] or [NO3
-
] delta. IV, intravenous.  
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